Benjamin F. Edwards & Company’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Benjamin F. Edwards & Company’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$9K	–	1940
2022 Q4	$9K	Hold	10,000	–	–	﹤0.01%	1463
2022 Q3	$16K	Hold	10,000	–	–	﹤0.01%	1309
2022 Q2	$20K	Hold	10,000	–	–	﹤0.01%	1249
2022 Q1	$23K	Hold	10,000	–	–	﹤0.01%	1209
2021 Q4	$47K	Hold	10,000	–	–	﹤0.01%	1069
2021 Q3	$76K	Hold	10,000	–	–	﹤0.01%	922
2021 Q2	$97K	Sell	10,000 -10,000	-50%	-$79.6K	﹤0.01%	854
2021 Q1	$165K	Buy	+20,000	New	+$211K	0.01%	721
2020 Q3	–	Sell	-400	Closed	-$3K	–	1794
2020 Q2	$3K	Buy	+400	New	+$1.53K	﹤0.01%	1554

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Benjamin F. Edwards & Company's SRNE Position: Q1 2023 in Review

Benjamin F. Edwards & Company sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 10,000 shares — an estimated $9K sold.

Benjamin F. Edwards & Company first reported a position in SRNE in Q2 2020 and held it in 9 quarters. The position peaked at $165K in Q1 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Benjamin F. Edwards & Company reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Benjamin F. Edwards & Company sold 10,000 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $9K.
Benjamin F. Edwards & Company first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 9 quarters.
Benjamin F. Edwards & Company's Sorrento Therapeutics, Inc. position peaked at $165K in Q1 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2023, filed 27 Apr 2023.